Evidence map›Paper›PMID 41542044›Full record

ArticleResearch square2026

Selective blockade of microRNA-31-5p/calcitonin receptor interaction reverses established atrial fibrosis and atrial arrhythmia substrate.

Jasha Trompf, Kathryn Cox, Mohit Hulsurkar, Lucia M Moreira, Chi Him Kendrick Yiu, Aaron M Johnston, Satadru K Lahiri, Shuai Zhao, Paul Robinson, Roddy Hiram and 18 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Jasha TrompfDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, British Heart Foundation Centre of Research Excellence, University of Oxford, John Radcliffe Hospital; Oxford, OX3 9DU, UK.
Kathryn CoxDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, British Heart Foundation Centre of Research Excellence, University of Oxford, John Radcliffe Hospital; Oxford, OX3 9DU, UK.
Mohit HulsurkarCardiovascular Research Institute, Baylor College of Medicine; One Baylor Plaza, BCM335, Houston, USA.
Lucia M MoreiraDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, British Heart Foundation Centre of Research Excellence, University of Oxford, John Radcliffe Hospital; Oxford, OX3 9DU, UK.
Chi Him Kendrick YiuDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, British Heart Foundation Centre of Research Excellence, University of Oxford, John Radcliffe Hospital; Oxford, OX3 9DU, UK.ORCID 0000-0001-8070-972X
Aaron M JohnstonDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, British Heart Foundation Centre of Research Excellence, University of Oxford, John Radcliffe Hospital; Oxford, OX3 9DU, UK.ORCID 0000-0002-7836-4221
Satadru K LahiriCardiovascular Research Institute, Baylor College of Medicine; One Baylor Plaza, BCM335, Houston, USA.ORCID 0000-0001-9502-1530
Shuai ZhaoCardiovascular Research Institute, Baylor College of Medicine; One Baylor Plaza, BCM335, Houston, USA.
Paul RobinsonDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, British Heart Foundation Centre of Research Excellence, University of Oxford, John Radcliffe Hospital; Oxford, OX3 9DU, UK.ORCID 0000-0002-3918-4420
Roddy HiramFaculty of Medicine, Department of Pharmacology and Physiology, and Research Centre, Montreal Heart Institute and University of Montreal; 5000 Bélanger Street Montréal (Quebec) H1T 1C8, Canada.ORCID 0000-0003-4291-8314
Mozhdeh MehdizadehFaculty of Medicine, Department of Pharmacology and Physiology, and Research Centre, Montreal Heart Institute and University of Montreal; 5000 Bélanger Street Montréal (Quebec) H1T 1C8, Canada.
Lorena Perez CarrilloDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, British Heart Foundation Centre of Research Excellence, University of Oxford, John Radcliffe Hospital; Oxford, OX3 9DU, UK.
Rana SayeedCardiothoracic Surgery, Oxford Heart Centre, John Radcliffe Hospital; Oxford, OX3 9DU, UK.ORCID 0000-0002-2887-1874
George KrasopoulosCardiothoracic Surgery, Oxford Heart Centre, John Radcliffe Hospital; Oxford, OX3 9DU, UK.
Vivek SrivastavaCardiothoracic Surgery, Oxford Heart Centre, John Radcliffe Hospital; Oxford, OX3 9DU, UK.
Nicholas WalcotCardiothoracic Surgery, Oxford Heart Centre, John Radcliffe Hospital; Oxford, OX3 9DU, UK.
Shakil FaridCardiothoracic Surgery, Oxford Heart Centre, John Radcliffe Hospital; Oxford, OX3 9DU, UK.
Antonios KourliourosCardiothoracic Surgery, Oxford Heart Centre, John Radcliffe Hospital; Oxford, OX3 9DU, UK.
Priya SastryCardiothoracic Surgery, Oxford Heart Centre, John Radcliffe Hospital; Oxford, OX3 9DU, UK.
David A MenassaClinical Neurology, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital; Oxford, OX3 9DU, UK.ORCID 0000-0002-5984-8407
Benjamin DaviesDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, British Heart Foundation Centre of Research Excellence, University of Oxford, John Radcliffe Hospital; Oxford, OX3 9DU, UK.
Rita A SchackDepartment of Integrative Physiology, Baylor College of Medicine; One Baylor Plaza BCM335, Houston, USA.
Robia G PautlerDepartment of Integrative Physiology, Baylor College of Medicine; One Baylor Plaza BCM335, Houston, USA.
Keith M ChannonDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, British Heart Foundation Centre of Research Excellence, University of Oxford, John Radcliffe Hospital; Oxford, OX3 9DU, UK.ORCID 0000-0002-1043-4342
Craig LygateDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, British Heart Foundation Centre of Research Excellence, University of Oxford, John Radcliffe Hospital; Oxford, OX3 9DU, UK.
Stanley NattelFaculty of Medicine, Department of Pharmacology and Physiology, and Research Centre, Montreal Heart Institute and University of Montreal; 5000 Bélanger Street Montréal (Quebec) H1T 1C8, Canada.ORCID 0000-0002-5565-3311
Xander H T WehrensCardiovascular Research Institute, Baylor College of Medicine; One Baylor Plaza, BCM335, Houston, USA.ORCID 0000-0001-5044-672X
Svetlana ReillyDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, British Heart Foundation Centre of Research Excellence, University of Oxford, John Radcliffe Hospital; Oxford, OX3 9DU, UK.ORCID 0000-0003-1231-1239

Funding

Ryanodine receptor regulation in post-operative atrial fibrillationR01HL089598 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI WEHRENS, XANDER H.T. · 2007 to 2022
$6.5M
Role of Nucleoside-Diphosphate Kinase Signaling in Atrial FibrillationR01HL160992 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI Xander H.T. Wehrens · 2023 to 2026
$2.1M
Mechanisms underlying atrial fibrillation associated with chronic kidney diseaseR01HL147108 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI LI, NA, WEHRENS, XANDER H.T. · 2019 to 2022
$2.0M
NHLBI NIH HHS R01 HL089598NHLBI NIH HHS R01 HL147108NHLBI NIH HHS R01 HL160992
6 · The paper itself

Abstract

Atrial fibrillation (AF), the commonest cardiac arrhythmia, is a major contributor to mortality and morbidity. Atrial tissue fibrosis, a hallmark of structural remodelling in AF, is currently incurable and significantly hinders AF-treatment.

Identifiers

PMID41542044
PMCPMC12803350

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.